146 related articles for article (PubMed ID: 38022448)
21. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
Whittle HC; Maine N; Pilkington J; Mendy M; Fortuin M; Bunn J; Allison L; Howard C; Hall A
Lancet; 1995 Apr; 345(8957):1089-92. PubMed ID: 7715343
[TBL] [Abstract][Full Text] [Related]
23. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan.
Su FH; Bai CH; Chu FY; Lin YS; Su CT; Yeh CC
Vaccine; 2012 Jun; 30(27):4034-9. PubMed ID: 22531558
[TBL] [Abstract][Full Text] [Related]
24. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009].
Yan B; Lyu J; Liu J; Feng Y; Xu A; Chen S; Zhou L; Liang X; Cui F; Wang F; Zhang L
Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Dec; 48(12):1043-7. PubMed ID: 25619213
[TBL] [Abstract][Full Text] [Related]
25. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang A; Wu Y; Tan Y; Shi J; Zhao Y; Hu Y; Yu J; Zheng W; Lai X; Zhang M; Zhu Y; Ye Y; Huang Y; Fu S; Huang H; Luo Y
Biol Blood Marrow Transplant; 2020 May; 26(5):956-964. PubMed ID: 31962163
[TBL] [Abstract][Full Text] [Related]
26. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
27. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
28. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
29. Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review.
Kelsey A; Casinelli G; Tandon M; Sriwastava S
J Cent Nerv Syst Dis; 2021; 13():11795735211037785. PubMed ID: 34497472
[TBL] [Abstract][Full Text] [Related]
30. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
31. Effect of obligatory Hepatitis B vaccination program on the prevalence of occult hepatitis B among pregnant women in Egypt: A cross sectional study.
Youssif RA; EzzEl-Din AM; Abd El-Hafeez HA; Sayed SK; Shaaban OM; Kamal DT
Egypt J Immunol; 2023 Oct; 30(4):101-110. PubMed ID: 37795902
[TBL] [Abstract][Full Text] [Related]
32. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
33. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
34. Immunization against Hepatitis B Surface Antigen (HBsAg) in a Cohort of Nursing Students Two Decades after Vaccination: Surprising Feedback.
Verso MG; Costantino C; Vitale F; Amodio E
Vaccines (Basel); 2019 Dec; 8(1):. PubMed ID: 31861551
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program.
Peto TJ; Mendy ME; Lowe Y; Webb EL; Whittle HC; Hall AJ
BMC Infect Dis; 2014 Jan; 14():7. PubMed ID: 24397793
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
37. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
S G; S L; C Z; A N; M F; L M
J Neurol; 2022 Jan; 269(1):39-43. PubMed ID: 34189719
[TBL] [Abstract][Full Text] [Related]
38. Two cases of meningitis associated with ocrelizumab therapy.
Theriault M; Solomon AJ
Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
40. Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab.
Rapisarda L; Valentino P; Barone S; Torti C; La Gamba V; Fortunato F; Sammarra I; Gambardella A
Clin Immunol; 2021 Feb; 223():108554. PubMed ID: 32777270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
